Ignite Creation Date:
2024-05-06 @ 1:45 AM
Last Modification Date:
2024-10-26 @ 11:08 AM
Study NCT ID:
NCT01883362
Status:
COMPLETED
Last Update Posted:
2021-03-17
First Post:
2013-03-25
Brief Title:
Standard of Care - Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis